Last reviewed · How we verify
other DOACs
At a glance
| Generic name | other DOACs |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin. (PHASE3)
- International Care Bundle Evaluation in Cerebral Hemorrhage Research (PHASE4)
- DOAC - Dosing Options in AntiCoagulation Prophylaxis (PHASE3)
- Short-term Interruption Versus Continuous Anticoagulation in Colorectal Polypectomy (PHASE4)
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation (PHASE4)
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) (PHASE4)
- EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- other DOACs CI brief — competitive landscape report
- other DOACs updates RSS · CI watch RSS
- Bayer portfolio CI